Sirolimus with or without cyclosporin for aplastic anemia

This study tests whether adding a medication called sirolimus to steroid treatment works better than steroids alone for newly diagnosed autoimmune hemolytic anemia (a condition where your body attacks its own red blood cells). You'll be randomly assigned to one treatment group, and researchers will track how well each approach helps your body recover.

This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.

This trial tests whether adding a platelet-boosting medicine (rhTPO) to a standard immune-suppressing drug (cyclosporine) works better than cyclosporine alone for people with aplastic anemia who need regular blood transfusions. The goal is to improve blood counts and reduce the need for transfusions.

This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.

This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.

This trial tests a new drug called ropustine to see if it can help people with aplastic anemia that hasn't responded to other treatments. The study is at one hospital and will monitor how well your blood counts and symptoms improve.